Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 3

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 3
---
30,596,858) 
    $643,037 

    Stock-based compensation 
     -  
     -  
     1,375,686  
     -  
     1,375,686 
  
    Net loss 
     -  
     -  
     -  
     (2,179,828) 
     (2,179,828)
  
    Balances, March 31, 2025 
     29,762,671  
     -  
     32,615,580  
     (32,776,686) 
     (161,106)
  
    Issuance of common stock for cash in ATM, net 
     18,299  
     -  
     47,769  
     -  
     47,769 
  
    Issuance of common stock for cash, Related party 
     333,334  
     -  
     1,000,000  
     -  
     1,000,000 
  
    Issuance of common stock for services 
     400,000  
     -  
     840,000  
     -  
     840,000 
  
    Stock-based compensation 
     -  
     -  
     3,824,450  
     -  
     3,824,450 
  
    Net loss 
     -  
     -  
     -  
     (5,069,890) 
     (5,069,890)
  
    Balances, June 30, 2025 
     30,514,304  
     -  
     38,327,799  
     (37,846,576) 
     481,223 
  
    Balances 
     30,514,304  
     -  
     38,327,799  
     (37,846,576) 
     481,223 

    Issuance of common stock for cash in ATM, net 
     2,650,000  
     -  
     5,502,239  
     -  
     5,502,239 
  
    Issuance of common stock for cash,